0000899243-16-021118.txt : 20160527 0000899243-16-021118.hdr.sgml : 20160527 20160527160635 ACCESSION NUMBER: 0000899243-16-021118 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160525 FILED AS OF DATE: 20160527 DATE AS OF CHANGE: 20160527 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ENRIGHT PATRICK G CENTRAL INDEX KEY: 0001253886 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 161682446 MAIL ADDRESS: STREET 1: CO LONGITUDE CAPITAL PARTNERS LLC STREET 2: 800 EL CAMINO REAL, SUITE 220 CITY: MENLO PARK STATE: CA ZIP: 94025 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-05-25 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001253886 ENRIGHT PATRICK G C/O LONGITUDE CAPITAL PARTNERS II, LLC 800 EL CAMINO REAL, SUITE 220 MENLO PARK CA 94025 1 0 0 0 Common Stock, $0.0001 par value 7513134 I By: Longitude Venture Partners II, L.P. Stock Option (right to buy) 15.40 2016-05-25 4 A 0 19755 0.00 A 2026-05-25 Common Stock 19755 19755 D The shares are held by Longitude Venture Partners II, L.P. ("Longitude Venture II"). Longitude Capital Partners II, LLC ("Longitude Capital II") is the general partner of Longitude Venture II and may be deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Patrick G. Enright is a managing member of Longitude Capital II and in his capacity as such may be deemed to exercise shared voting and investment power over the shares held by Longitude Venture II. Mr. Enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2017 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. /s/ Warren L. DeSouza, as Attorney-in-Fact for Patrick G. Enright 2016-05-27